2018-08-22
Ark Biosciences to Present Efficacy Data on Novel Ziresovir at an International Conference
Ark to present efficacy data on its novel RSV F-protein inhibitor, Ziresovir (AK0529) at the 11th International RSV Symposium in Asheville, North Carolina, USA, 31st October – 4th November 2018...
know more >
2018-07-25
Ark Biosciences Licenses a Clinical Stage Drug for Treatment of Idiopathic Pulmonary Fibrosis
Ark announced a license agreement for a Roche's potential drug for idiopathic pulmonary fibrosis...
know more >
2018-08-13
Ark Biosciences and KOLs Published a Review Paper on Antiviral Drug Resistance Across Chronic and Acute Infections
Antiviral therapy can lead to drug resistance, but multiple factors determine the frequency of drug resistance mutations and the clinical consequences...
know more >
2017-11-08
Ark Biosciences and Calibr Announce Joint Development of First-in-Class Chronic Obstructive Pulmonary Disease Drug
Ark announced a collaboration with the Calibr to jointly develop novel first-in-class drugs for the treatment of Chronic Obstructive Pulmonary Disease (COPD) and related lung diseases...
know more >
2016-08-18
Ark Biosciences Initiates VICTOR Study
Ark Biosciences announced that dosing with AK0529, its leading antiviral drug against respiratory syncytial virus (RSV), has commenced in infants hospitalized with RSV infection in the VICTOR study...
know more >